Advanced or Metastatic Solid Tumor Completed Phase 1 Trials for Selumetinib (DB11689)

Also known as: Advanced / Metastatic Solid Tumor / Advanced/Metastatic Solid Tumor / Advanced and Metastatic Solid Tumor / Metastatic and Advanced Solid Tumors / Advanced and/or Metastatic Solid Tumors / Advanced or Metastatic Solid Tumors / Advanced / Metastatic Solid Tumors / Advanced/ Metastatic Solid Tumors / Advanced/Metastatic Solid Tumors

IndicationStatusPhase
DBCOND0109909 (Advanced or Metastatic Solid Tumor)Completed1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03833427Study of Selumetinib (MK-5618) in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Solid Tumors (MK-5618-001)Treatment